<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04863144</url>
  </required_header>
  <id_info>
    <org_study_id>FMASU MD 8/2020</org_study_id>
    <nct_id>NCT04863144</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Paclitaxel in Correlation With Adverse Events in Cancer Patients With and Without Liver Impairment</brief_title>
  <official_title>Effect of CYP3A4 and CYP2C8 Activity on Pharmacokinetics of Paclitaxel, Correlation With Adverse Events in Cancer Patients With and Without Liver Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to assess the pharmacokinetics of paclitaxel and its two major metabolites in&#xD;
      patients with normal and impaired liver functions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      population pharmacokinetic study in patients with normal or impaired liver functions,&#xD;
      receiving paclitaxel for cancer treatment.&#xD;
&#xD;
      40 Patients with histologically confirmed solid tumors will be enrolled in the study:&#xD;
&#xD;
        -  20 patients have normal liver functions as defined by transaminase &lt; 2.6 x ULN and&#xD;
           bilirubin values &lt; 1.26 x ULN.&#xD;
&#xD;
        -  20 patients with liver impairment as defined by transaminase 2.6 - 10 x ULN and&#xD;
           bilirubin values 1.26 - 5 x ULN.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2020</start_date>
  <completion_date type="Anticipated">February 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>plasma concentrations of paclitaxel</measure>
    <time_frame>predose till 6 hours post infusion of paclitaxel</time_frame>
    <description>determination of plasma concentration and pharmacokinetic analysis of paclitaxel</description>
  </primary_outcome>
  <primary_outcome>
    <measure>plasma concentrations of 6-α-hydroxypaclitaxel</measure>
    <time_frame>predose till 6 hours post infusion of paclitaxel</time_frame>
    <description>determination of plasma concentration and pharmacokinetic analysis of 6-α-hydroxypaclitaxel</description>
  </primary_outcome>
  <primary_outcome>
    <measure>plasma concentrations of 3'-p-hydroxypaclitaxel</measure>
    <time_frame>predose till 6 hours post infusion of paclitaxel</time_frame>
    <description>determination of plasma concentration and pharmacokinetic analysis of 3'-p-hydroxypaclitaxel</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Probing CYP 3A4 activity</measure>
    <time_frame>predose till 6 hours post infusion of paclitaxel</time_frame>
    <description>metabolite ratio of 6-α-hydroxypaclitaxel/paclitaxel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Probing CYP 2C8 activity</measure>
    <time_frame>predose till 6 hours post infusion of paclitaxel</time_frame>
    <description>metabolite ratio of 3'-p-hydroxypaclitaxel/paclitaxel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse effects</measure>
    <time_frame>baseline ( before first dose) till 100 days after the first dose</time_frame>
    <description>Complete blood count, liver functions and neuropathy evaluation (according to Common Terminology Criteria for Adverse Events (CTCAE), version 5) will be assessed</description>
  </secondary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Liver Diseases</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood samples</intervention_name>
    <description>Plasma concentrations of paclitaxel and its metabolites will be obtained during the first treatment cycle. The samples for paclitaxel analysis will be collected in ethylenediamine tetraacetic acid tubes at 7-time points: just before infusion, in the middle of the infusion, at the end of infusion, at 1, 2, 4 and 6 hours post-infusion.</description>
  </intervention>
  <biospec_retention>None Retained</biospec_retention>
  <biospec_descr>
    <textblock>
      plasma&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        40 Patients with histologically confirmed solid tumors and are going to receive paclitaxel&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with histologically proven non haematopoietic malignancy (ovarian, breast and&#xD;
             lung cancer).&#xD;
&#xD;
          -  Age between 18 and 70 years&#xD;
&#xD;
          -  At least a 4-week interval between the last dose of previous chemotherapy protocol and&#xD;
             registration (6 weeks in case of treatment with carboplatin).&#xD;
&#xD;
          -  Glomerular filtration rate &gt; 60 ml/min&#xD;
&#xD;
          -  An Eastern Cooperative Oncology Group performance status 0-2, a life expectancy of &gt;&#xD;
             12 weeks, adequate bone marrow function [absolute neutrophil count (ANC) ≥ 1 X 109 and&#xD;
             platelets ≥ 100 X 109]&#xD;
&#xD;
          -  Patient accessible for treatment and follow-up and written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with paclitaxel or other taxanes.&#xD;
&#xD;
          -  Pre-existing motor or sensory neurotoxicity &gt; grade 2 according to World Health&#xD;
             Organization (WHO) criteria.&#xD;
&#xD;
          -  Active infection or other serious underlying medical condition (including prior&#xD;
             allergic reactions to Paclitaxel or the drug's constituents), dementia or&#xD;
             significantly altered mental status, symptomatic brain or liver metastases, history of&#xD;
             atrial or ventricular arrhythmias or congestive heart failure even if medically&#xD;
             controlled, history of clinical and electrocardiographically documented myocardial&#xD;
             infarction.&#xD;
&#xD;
          -  Simultaneous use of any medication, dietary supplements, or other compounds known to&#xD;
             inhibit affect the pharmacokinetics of paclitaxel.&#xD;
&#xD;
          -  Patients with difficult blood sampling.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed Nour-Eldin, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Pharmacology Department - Faculty of Medicine - Ain Shams University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Khaled Abdel-Aziz, MD</last_name>
    <role>Study Director</role>
    <affiliation>Oncology Department - Faculty of Medicine - Ain Shams University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ahmed M Mohamed, Master</last_name>
    <phone>01126109080</phone>
    <email>dr_ahmed_mostafa@med.asu.edu.eg</email>
  </overall_contact>
  <location>
    <facility>
      <name>El Demerdash Oncology Hospital</name>
      <address>
        <city>Cairo</city>
        <state>Abbasia</state>
        <zip>11865</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmed M Mohamed, Master</last_name>
      <phone>01126109080</phone>
      <email>dr_ahmed_mostafa@med.asu.edu.eg</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 21, 2021</study_first_submitted>
  <study_first_submitted_qc>April 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2021</study_first_posted>
  <last_update_submitted>April 27, 2021</last_update_submitted>
  <last_update_submitted_qc>April 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Paclitaxel</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Egypt</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

